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Background. HIV-infected patients are at increased risk of myocardial infarction and arterial
inflammation has been suggested as a pathophysiological explanation. We compared the uptake of 18F-
fluorodeoxyglucose (FDG) by PET in four arterial regions, and factors associated with FDG uptake in
well-treated HIV-infected patients without cardiovascular disease (CVD) and healthy controls.
Methods and Results. We prospectively scanned 26 HIV-infected patients on stable antiret-
roviral therapy and 25 healthy volunteers with FDG PET/CT, measuring standardized uptake
values (SUV) in the carotid arteries, the ascending, descending, and abdominal aorta. We performed
correlation analyses between FDG uptake and intima-media thickness (IMT), and soluble bio-
markers of inflammation. We found no difference in arterial FDG uptake between the HIV-infected
patients and healthy controls quantified either as mean SUVmax or target-to background ratio in the
carotid region, the ascending aorta, the descending aorta, or the abdominal aorta. Correlations
between SUV, IMT, and soluble biomarkers were scarce in both groups.
Conclusion. In a group of optimally treated HIV-infected patients with full viral suppression, low
Framingham risk score and no known CVD, we found no evidence of increased arterial inflammation
as assessed by FDG PET/CT compared to healthy volunteers. (J Nucl Cardiol 2015;22:372–80.)
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INTRODUCTION
HIV-infected patients are at increased risk of
myocardial infarction (MI)1 and subclinical coronary
atherosclerosis even when low HIV RNA levels and
high CD 4 cell counts are obtained with antiretroviral
therapy (ART),2-4 however, the mechanism behind
remains to be fully elucidated. Both the HIV infection
itself and the ART have been shown to cause chronic
inflammation and endothelial dysfunction,5-7 associated
with upregulation of adhesion molecules marking the
beginning of an atherosclerotic lesion.8 In HIV-infected
patients these lesions seem to be less calcified3,9
making them more vulnerable and prone to rupture.10
Macrophages are known to play a key role in the
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development of atherosclerosis11 and recently a possi-
ble mechanistic role has been ascribed to the
macrophage in causing the increased risk12-14 among
HIV-infected patients.
The activated macrophage has a high metabolic rate
and is therefore readily visualized by positron emission
tomography (PET) using the glucose analog 18F-fluoro-
deoxyglucose (FDG).15 If increased inflammatory
activity is present in arteries of HIV-infected we would
expect an increased FDG uptake compared to the
arteries in comparable healthy controls. Studies of this
very early atherosclerosis would provide knowledge of
the pathogenesis behind the increased risk of cardiovas-
cular disease (CVD) among HIV-infected patients with
full viral suppression and may also offer ways to
monitor early atherosclerosis and guide future interven-
tions against CVD in this population.
We conducted a cross-sectional, prospective study
of 26 HIV-infected patients and 25 healthy controls
using FDG PET/CT with the concomitant measurement
of intima-media thickness (IMT), soluble biomarkers of




A total of 53 persons were scanned between March 2011
and June 2013.
Twenty-six HIV-infected patients were prospectively
recruited at routine visits at the out-patient clinic at the
department of infectious diseases, Copenhagen University
Hospital, Hvidovre, Denmark.
Inclusion criteria were HIV-infection, male sex,
age [ 18 years, and ART [ 12 months and exclusion criteria
were known CVD (myocardial infarction, stable/unstable
angina, arrhythmia, peripheral arterial disease, or stroke),
diabetes mellitus, renal insufficiency, or use of lipid lowering
drugs.
A total of 27 healthy volunteers were recruited prospec-
tively through online advertising using the same exclusion
criteria.
Of the 27 healthy volunteers 2 were excluded due to the
incidental finding of a minor thymoma and pulmonary cancer
on the PET/CT-scans, respectively.
Ethics
All patients received oral and written information and
gave written consent before inclusion. The study was approved
by the Scientific Ethics Committee of The Capital Region of
Denmark [protocol number H-4-2010-044] and complied with
the declaration of Helsinki.
PET/CT-Scans
After an overnight fast, 400 MBq (10.8 mCi) FDG was
injected by auto-injector, and to reduce tracer uptake in neck
and mouth muscles and brown fat, the patients were not
allowed to talk and rested in calm and warm surroundings from
15 minutes before injection to 30 minutes after injection.
Three hours after injection, the scan was performed on a
combined PET/CT-scanner (Siemens Biograph mCT64, Sie-
mens, Erlangen, Germany). Each participant underwent a
CT-scan from the arcus zygomaticus to the crista iliaca for
attenuation correction and after the PET-scan a CT-scan with
intravenous contrast (Optiray) in arterial phase for better
visualization of the carotid arteries. The CT-scan used 120 kV,
225 mAs (care dose). Slice thickness was 2 mm.
The PET-scan was performed with 3-4 bed positions
depending of the height of the patient covering the area from
the arcus zygomaticus to the crista iliaca. PET acquisition time
was 3 minutes per bed position in 3D list mode. The system
used both resolution-recovery (point spread function, TrueX),
time-of-flight, and OSEM (2 iterations, 21 subsets, zoom 1.0)
giving 400 9 400 image slices (voxel size 2.04 9
2.04 9 2.00 mm).
PET/CT Image Reconstruction
Four anatomical areas were chosen per protocol for
analysis: the carotid arteries (a. carotis interna, sinus carot-
icus, and a. carotis communis), the ascending aorta (pars
ascendens aortae—cranially to the coronary sinus), the
descending aorta (pars thoracica aortae), and the abdominal
aorta (pars abdominalis aortae). For the correlation analysis of
the IMT and FDG uptake a mean SUVmax for the common
carotid artery on both sides was calculated (Figure 1).
Image analysis was performed on InveonTM Research
Workplace (Siemens, Erlangen, Germany) by the same analyst
using a standard protocol. Regions of interest (ROI) were
manually drawn slice by slice including both vessel wall and
lumen. Standardized uptake values (SUV) were calculated by
dividing the decay-corrected radioactivity concentration
(MBqL-1) by the injected radioactive dose per body weight
(MBqkg-1) assuming a mass density of body tissue of
1 kgL-1.
For each region a mean arterial SUVmax was calculated.
The target-to-background ratio (TBR) was calculated by
dividing the mean SUVmax by the mean SUV from the vena
cava superior.
Plasma Markers
Plasma samples were analyzed using commercially
available kits according to the manufacturer’s instructions.
High sensitivity C-reactive protein (hsCRP) was measured on a
Siemens STRATUS CS in duplicate with a coefficient of
variance (CV) of 8.6%.
Soluble CD163 (sCD163) was measured by an in-house
sandwich enzyme-linked immunosorbent assay using a BEP-
2000 ELISA-analyser (Dade Behring, Deerfield, IL, USA).16
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Soluble endothelial selectin (sE-selectin), soluble vascular
cell adhesion molecule1 (sVCAM-1), soluble intercellular
adhesion molecule 1 (sICAM-1), matrix metalloprotease 9
(MMP-9), and total plasminogen activator inhibitor 1 (PAI-1)
were analyzed on a multiplex assay (Milipore Corporation,
MA, USA) using Luminex technology.
All samples were run in duplicates with CV \ 12%. CD4
cell counts and HIV RNA levels were done routinely on blood
and plasma when collected. Serum lipids were analyzed on a
MODULAR ISE 1800 (Roche, Basel, Switzerland).
Metabolic syndrome was defined as having at least two of
the following: fasting blood glucose C 5.6 mmolL-1 or (sys-
tolic blood pressure C 135 mm Hg or diastolic blood
pressure C 85 mm Hg) or (triglycerides [ 1.7 mmolL-1 or
high density lipoprotein \1.03 mmolL-1).17
Framingham risk score (FRS) was calculated as the
10-year risk of coronary heart disease (CHD) according to
published definitions.18
Intima-Media Thickness
Before tracer injection, real-time IMT was measured in
the common carotid artery 1 cm caudally of the sinus
caroticus by ultrasound (Mylab25Gold, Esaote, Italy) using
a 6.5 MHz transducer and automatic software (RF-QIMT,
Esaote, Italy).
Statistics
Data are reported as mean values ± standard error of the
mean.
The HIV-infected patients and the healthy controls were
compared using unpaired t test. Variables were tested for
normal distribution using the Kolmogorov-Smirnov-test and
log-transformed to obtain a normal distribution and analyzed
by parametric test. Correlations were analyzed using Spear-
man’s q on untransformed data.
The adjusted unpaired t-test was performed by multiple
linear regression, and test for interaction was performed with a
general linear model.
We performed a Bonferroni correction for multiple
comparisons in the correlation analysis, and we therefore
considered a p-value of .0125 significant.
With a total of 51 patients in the two groups we obtained a
power of 0.8 to detect a difference of *18% in FDG uptake
(alpha 0.05) using previously published standard deviation on
SUVmax from arteries.
19
One healthy control did not have blood drawn and
another healthy control was not scanned over the neck
region. Two healthy controls had missing data on blood
pressure.
All statistics were performed using SPSS 20 (IBM
SPSS statistics for windows, version 20.0 Armonk, NY,
IBM Corp).
RESULTS
The characteristics of the HIV-infected group and
healthy controls are shown in Table 1.
The HIV-infected group was older (50.5 ± 2.4 vs
41.2 ± 2.6 yrs; p = .01) and had higher blood pressure
and total cholesterol, and accordingly a higher FRS.
Three HIV-infected patients and 1 healthy control had
metabolic syndrome.
HIV-Parameters
The HIV-infected group was stable on ART with a
mean CD 4 cell count of 636 (106/L), and all had viral
loads \40 copies/mL. A total of 21/25 (81%) of the
HIV-infected individuals received a regimen of 2
nucleoside reverse transcriptase inhibitors (NRTIs)
and 1 non-nucleoside reverse transcriptase inhibitor
(NNRTI), whereas 15% received a regimen including a
protease inhibitor (PI) (Table 1).
Figure 1. CT-angiography showing the areas of the arterial
tree where regions of interest (ROI) were drawn for the
analysis of FDG uptake. Slice thickness on CT was 2 mm, but
distances on this image are not to actual scale.
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Markers of Endothelial Dysfunction and
Inflammation
The plasma level of the coagulation marker, PAI-1, was
significantly higher in the HIV-infected group than among
healthy controls (38.6 ± 1.8 vs 28.7 ± 3.3 ngmL-1;
p = .009). However, the levels of soluble biomarkers of
inflammation (hsCRP), activated macrophages (CD163),
and endothelial dysfunction (E-Selectin, VCAM-1, ICAM-
1, MMP-9) did not differ between the two groups (Figure 2).
Inter Group Differences in Arterial Wall
FDG Uptake
The two groups displayed no significant differences
in mean SUVmax in the carotid region (1.67 ± 0.04 vs
1.67 ± 0.04, p = .98), the ascending aorta (1.84 ± 0.06
vs 1.97 ± 0.06, p = .15), the descending aorta
(1.89 ± 0.08 vs 1.93 ± 0.08, p = .70), or the abdominal
aorta (1.70 ± 0.06 vs 1.65 ± 0.06, p = .56), HIV-
infected vs healthy controls, respectively. The two
groups also displayed similar values of TBR in the four
regions: 3.59 ± 0.20 vs 3.25 ± 0.19, p = .16 in the
carotid region; 4.00 ± 0,25 vs 3.77 ± 0.17, p = .64 in
the ascending aorta; 4.04 ± 0,23 vs 3.71 ± 0.21, p = .31
in the descending aorta; and 3.64 ± 0,20 vs 3.24 ± 0.23,
p = .11 in the abdominal aorta (Figures 3A, B, 4), and
these findings remained unchanged when adjusting the
analysis for the variables by which the groups were
significantly different, i.e., age, systolic blood pressure,
diastolic blood pressure, total cholesterol, and blood
glucose (Data not shown).
Table 1. Baseline characteristics
HIV-infected Healthy controls
p value*Mean 95% CI Mean 95% CI
Number 26 25
Male gender 26 (100) 25 (100)
Age (years) 50.5 45.5-55.5 41.2 35.8-46.5 .01
Tobacco use
Current, n (%) 5 (19) 7 (28) .23
Former, n (%) 11 (42) 5 (20)
Never, n (%) 10 (39) 13 (52)
Statin use 0 0
Hemodynamics
Systolic blood pressure (mm Hg) 134 128-141 127 122-133 .09
Diastolic blood pressure (mm Hg) 82 78-86 74 70-78 .004
Risk calculations
Framingham 10 yr CHD risk (%) 7.8 5.4-10.2 4.1 2.1-6-1 .03
Lipid profile
Total cholesterol (mmolL-1) 5.3 4.8-5.9 4.6 4.0-5.1 .03
HDL (mmolL-1) 1.6 1.3-1.8 1.5 1.4-1.7 .63
LDL (mmolL-1) 3.2 2.8-3.6 2.8 2.2-3.3 .18
TG (mmolL-1) 1.3 1.0-1.6 1.1 0.9-1.2 .14
Blood glucose (mmolL-1) 5.4 5.1-5.7 4.9 4.7-5.1 .01
BMI 24.0 22.9-25.1 24.8 23.7-26.0 .28
HIV parameters
CD4 cell count (106)L-1 636 549-717
HIV duration (years) 13.9 10.8-16.8
ART duration (years) 9.9 8-11.7
HIV RNA copies/mL (median, range) 19 19-31
C2 NRTIs ? 1 NNRTI (%) 21 (81)
C2 NRTIs ? C1 PI (%) 4 (15)
Other (%) 1 (4)
*Unpaired t-test. v2-test
ART, antiretroviral therapy; BMI, body mass index; CHD, coronary heart disease; HDL, high density lipoprotein; LDL, low density
lipoprotein; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease
inhibitor; TG, triglycerides
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Intima-Media Thickness
No difference was found between the two groups in
mean IMT on the right (630 ± 26 vs 634 ± 21 lm;
p = .78), and the left (674 ± 26 vs 636 ± 25 lm;
p = .29), or in a mean value of the two sides
(652 ± 24 vs 635 ± 18 lm; p = .67), HIV-infected vs
healthy controls, respectively. The values remained
without statistical difference when adjusting for the
variables by which the groups differed, i.e., age, systolic
blood pressure, diastolic blood pressure, total choles-
terol, and blood glucose (Data not shown).
There was no correlation between IMT and FDG
uptake in the right (q = -0.115; p = .58) or left
(q = 0.398; p = .05) common carotid artery among
HIV-infected or healthy controls (q = -0.141;
p = .51), and (q = 0.261; p = .22), right and left
common carotid artery, respectively.
HIV Parameters and FDG Uptake
CD4 cell count was inversely correlated to FDG
uptake in the descending aorta (q = -0.707;
p \ .0001), whereas no correlations were found between
duration of HIV-infection, duration of ART or HIV
RNA viral load, and FDG uptake.
Biomarkers and FDG Uptake
In the HIV-infected group there were no correla-
tions between the soluble biomarkers of inflammation
Figure 2. Plasma levels of soluble biomarkers. Abbreviations: sCD163, soluble cluster of
differentiation 163. sE-selectin, soluble endothelial selectin. hsCRP, high sensitivity C-reactive
protein. sICAM-1, soluble intercellular adhesion molecule 1. MMP-9, matrix metalloprotease 9.
PAI-1, plasminogen activator inhibitor 1. sVCAM-1 soluble vascular cell adhesion molecule 1.
Boxes represent 25%-75% intervals and whiskers represent 90% confidence intervals. Asterisk
indicates p \ 0.05.
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and FDG uptake beside an inverse correlation between
sCD163 and FDG uptake in the descending aorta
(q = -0.517; p = .007). None were found in the
healthy control group.
As the only biomarker to be significantly different
between the two groups, PAI-1 was analyzed by a
multiple regression model and found independently
associated with FDG uptake in the carotid region and the
descending aorta (b = 0.224; p = .048) and
(b = 0.506; p = .006), respectively.
There was no interaction between HIV-status and
the soluble biomarkers.
DISCUSSION
There is a well-established link between macro-
phages and CVD, and with the correlation between
18F-FDG PET and macrophages,20 PET/CT-scan could
possibly be of use in the assessment of arterial inflam-
mation as sign of early CVD, which is of concern among
HIV-infected individuals.14 However, in this cross-sec-
tional study of 51 individuals, we did not find a difference
in FDG uptake in the arterial wall of four different regions
of the arterial tree between HIV-infected and healthy
controls. This result was surprising in the light of
previous studies of FDG uptake in HIV-infected patients.
First, Yarasheski et al performed a proof-of-concept
study among nine HIV-infected patients with known
cardiovascular risk factors and five healthy volunteers
and found proof of vascular inflammation in the HIV-
infected group, where eight out of nine patients had
evidence of carotid plaque.21 Another and larger study by
Subramanian et al found that HIV-infected patients
without CVD had higher FDG uptake in the ascending
aorta than a matched healthy control group with the
conclusion that HIV-infection was associated with arte-
rial inflammation. Further, this inflammation was found
to be associated with sCD163 among the HIV-infected
patients making macrophages the most likely suspects
behind the increased FDG uptake.14
Our study design differed in many ways from the
study by Subramanian et al first and foremost, we
prospectively included all participants to the exact same
imaging methodology on a single PET/CT-system, and
our PET examinations were therefore all performed
3 hours after FDG injection. The importance of similar
FDG circulation time was recently emphazised in
several studies.19,22 Especially the TBR has been shown
to increase over time due to the washout of FDG in the
lumen of the vessel (background), which happens faster
than the decay in the arterial wall.19,22,23 Therefore,
comparison of TBR values between HIV-infected
patients scanned after 3 hours with individuals scanned
after 60 minutes as per-clinical (oncological) protocol 24
as done in the trial by Subramanian et al could
potentially produce false high values among the HIV-
infected individuals.14
Our study population was very similar to the
participants included in the study by Subramanian
et al, but a few potentially important differences exist.
Their HIV-infected group had [40% of patients cur-
rently treated with PI vs 15% in our study, and since PI
have been shown to affect endothelial function this may
have an impact on the uptake of FDG.25
Moreover, we included no individuals treated with
statins, which are proven to have anti-inflammatory
effects and may have attenuated the FDG tracer uptake
26 among the healthy controls.
Our comparison of soluble biomarkers of inflam-
mation, macrophages activation and endothelial
Figure 3. A Mean SUVmax in the four regions for HIV-infected and healthy controls. B Target-to-
background ratio (TBR) in the four regions for HIV-infected and healthy controls. Boxes represent
25%-75% intervals and whiskers represent 90% confidence intervals.
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dysfunction as well as IMT supports our FDG results in
showing very few differences between optimally treated
HIV-infected patients with high CD 4 counts and full
viral suppression and healthy controls. The only soluble
biomarker that differed between the groups was the
marker of anti-fibrinolytic activity, PAI-1, which was
significantly higher in the HIV-infected group. Interest-
ingly, PAI-1 was also independently associated with
FDG uptake in two vascular regions in the HIV-infected
group. We have recently found an association between
increased levels of PAI-1 and the risk of MI among
HIV-infected patients,27 but whether the association
between PAI-1 levels and FDG uptake found in this
study constitutes a causal link between PAI-1 and CVD
remains to be elucidated.
The groups did not differ with regard to IMT, and
the correlation analysis of FDG uptake and IMT did not
show any significance. Indeed, both groups had IMT
levels within normal range.28
Our group of HIV-infected patients was carefully
selected not to have any known CVD or diabetes, which
was reflected in low FRS and normal IMT. This may
impair the ability to detect correlations with FDG uptake
since the association of FDG and macrophages is most
strongly shown in lesions from more advanced athero-
sclerosis.29,30 Further a recent ex vivo study suggests
Figure 4. Fusion PET/CT axial images from the ascending (panel A) and abdominal aorta (panel
B) of an HIV-infected patient and a healthy control showing modest FDG uptake in the arterial
wall. AA, abdominal aorta; FDG, fluorodeoxyglucose; SVC, superior vena cava.
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that hypoxia rather than the presence of macrophages is
correlated with FDG uptake.31 Taken together, our data
do imply that optimally treated HIV-infection in patients
with no known CVD and low FRS does not cause
arterial inflammation as assessed by biomarkers, IMT, or
FDG uptake.
However, it should be emphasized that conclusions
from this well-treated HIV-infected population do not
nescessarily extrapolate to non-selected populations,
where risk factors may be more prevalent.
LIMITATIONS
The sample size of 51 subjects is relatively small,
but had ample power to detect differences in FDG tracer
uptake in the aforementioned studies with FDG. The
small sample size limits the study’s ability to detect
differences between other parameters and as such more
subtle differences may have gone undetected while
others could have arisen by chance alone. Our two
groups were not perfectly matched and differences in
risk profile had to be adjusted for in the statistical
analyses. However, this difference would, if anything,
make the HIV-infected group more likely to have
arterial inflammation. To make full use of our scans we
included data from the descending and abdominal aorta
although a study showed higher interscan variability in
these areas compared to the carotid arteries and the
ascending aorta.32
NEW KNOWLEDGE GAINED
In this study we found no evidence of arterial
inflammation among optimally treated HIV-infected
patients with low cardiovascular risk and no known
CVD.
CONCLUSION
In a group of HIV-infected patients on stable ART
with full viral suppression, no known CVD and low FRS
we did not find evidence of arterial inflammation as
assessed by FDG uptake in four different regions of the
arterial wall compared to a group of healthy volunteers.
This may indicate that well-treated HIV-infection per se
is not associated with arterial inflammation.
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